Clinical journal of the American Society of Nephrology : CJASN

Guidelines for Using SGLT2 Inhibitors and GLP-1 Receptor Agonists to Treat Kidney Disease in Diabetes

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RA) are recommended for heart and kidney protection in diabetes management.

  • Diabetic kidney disease is linked with increased risks of kidney failure and cardiovascular mortality.
  • SGLT2i and GLP-1 RA have been shown to prevent cardiovascular events and kidney failure.
  • Clinical trials have shifted diabetes treatment toward prioritizing heart and kidney protection.
  • A decision-making tool is proposed to assist clinicians in evaluating the appropriateness of SGLT2i and GLP-1 RA for patients at high risk.
  • The effectiveness of SGLT2i and GLP-1 RA varies across different risk categories for cardiovascular and kidney outcomes.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Feb '19
Comparing Diabetes Drugs That Lower Blood Sugar for Preventing Heart and Kidney Problems in Type 2 Diabetes
top 1% journal
cited by 670 papers
systematic review
Aug '24
Kidney and heart benefits of SGLT2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes
top 1% journal
cited by 29 papers
comparative study
Nov '22
Comparing finerenone, SGLT2 inhibitors, and GLP-1 receptor agonists for heart and kidney outcomes in type 2 diabetes with chronic kidney disease
top 2% journal
cited by 77 papers
network meta-analysis
Jun '23
Death rates and heart health with SGLT2 inhibitors, GLP-1 receptor drugs, and their combination in type 2 diabetes
top 5% journal
cited by 49 papers
research support, non-u.s. gov't
Nov '23
Estimated Lifetime Heart, Kidney, and Survival Benefits of Combining Three Drugs Compared to Usual Care in Type 2 Diabetes Patients with Protein in Their Urine
top 1% journal
cited by 271 papers
case reports
Apr '23
Using GLP-1 receptor activators and SGLT2 inhibitors together in people with type 2 diabetes
top 2% journal
cited by 99 papers
research support, non-u.s. gov't
Jan '21
Comparing SGLT-2 inhibitors and GLP-1 receptor agonists for type 2 diabetes: review and analysis of clinical trials
top 5% journal
cited by 520 papers
systematic review
Aug '24
Real-world effects of adding a GLP-1 drug versus basal insulin on metabolism in adults with type 2 diabetes and kidney disease already on SGLT2 inhibitors
cited by 10 papers
comparative study

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
yesterday7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
1 week ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
2 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
3 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
4 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
5 weeks ago7 studies
issue #38
Two-thirds of patients kept weight off after stopping GLP-1 drugs
6 weeks ago7 studies
issue #36
Tirzepatide beats semaglutide for weight loss: 8.2% vs 5.8% body weight reduction at 12 months
8 weeks ago7 studies
issue #35
Semaglutide linked to 2.5x higher risk of sudden vision loss
9 weeks ago7 studies
issue #34
Tirzepatide users had 18.4% weight loss vs 11.9% with semaglutide in head-to-head trial
10 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief